Astrazeneca PlcLSE: AZN

Change to astrazeneca board of directors

· Issued by Astrazeneca Plc
RNS Number : 9770K
AstraZeneca PLC
28 September 2016
 

28 September 2016 07:00

CHANGE TO ASTRAZENECA BOARD OF DIRECTORS

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive Director, will step down from the Board of AstraZeneca PLC and as a member of the Company's Science Committee with effect from 1 October 2016.  Dr Bargmann recently accepted a new position as President of Chan Zuckerberg Science, part of the Chan Zuckerberg Initiative.

Leif Johansson, AstraZeneca Chairman, said:  "We congratulate Cori on her new appointment and thank her for her contribution to AstraZeneca in the last 18 months.  We are sorry to see her leave the AstraZeneca Board but fully understand her decision to step down to focus on her new assignment."

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

CONTACTS

Media Enquiries

Neil Burrows

UK/Global

+44 203 749 5637

Vanessa Rhodes

UK/Global

+44 203 749 5736

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Relations

UK

Thomas Kudsk Larsen

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Nick Stone

Respiratory & Autoimmunity

+44 203 749 5716

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Infection & Neuroscience

+44 203 749 5711

US

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Mitchell Chan

 Oncology

+1 240 477 3771

Toll-free

+1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAXDLFLQKFFBBB